157 related articles for article (PubMed ID: 19407853)
1. Expression of insulin-like growth factor 2 in mesenchymal neoplasms.
Steigen SE; Schaeffer DF; West RB; Nielsen TO
Mod Pathol; 2009 Jul; 22(7):914-21. PubMed ID: 19407853
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients.
Braconi C; Bracci R; Bearzi I; Bianchi F; Sabato S; Mandolesi A; Belvederesi L; Cascinu S; Valeri N; Cellerino R
Ann Oncol; 2008 Jul; 19(7):1293-1298. PubMed ID: 18372285
[TBL] [Abstract][Full Text] [Related]
4. Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours.
Italiano A; Chen J; Zhang L; Hajdu M; Singer S; DeMatteo RP; Antonescu CR
Eur J Cancer; 2012 Nov; 48(17):3215-22. PubMed ID: 22770876
[TBL] [Abstract][Full Text] [Related]
5. IGF2 is highly expressed in pediatric undifferentiated sarcomas and reveals two distinct cytoplasmic trafficking patterns.
Somers GR; Ho M; Pienkowska M; Shlien A; Malkin D; Ackerley C; Zielenska M
Pediatr Dev Pathol; 2010; 13(3):169-77. PubMed ID: 19586133
[TBL] [Abstract][Full Text] [Related]
6. Activating transcription factor 2 in mesenchymal tumors.
Endo M; Su L; Nielsen TO
Hum Pathol; 2014 Feb; 45(2):276-84. PubMed ID: 24289970
[TBL] [Abstract][Full Text] [Related]
7. Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications.
Lasota J; Wang Z; Kim SY; Helman L; Miettinen M
Am J Surg Pathol; 2013 Jan; 37(1):114-9. PubMed ID: 22892600
[TBL] [Abstract][Full Text] [Related]
8. High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event.
Rüping K; Altendorf-Hofmann A; Chen Y; Kampmann E; Gibis S; Lindner L; Katenkamp D; Petersen I; Knösel T
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1315-22. PubMed ID: 24804818
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
10. A case of insulin-like growth factor 2-producing gastrointestinal stromal tumor with severe hypoglycemia.
Yamasaki H; Itawaki A; Morita M; Miyake H; Yamamoto M; Sonoyama H; Tanaka S; Notsu M; Yamauchi M; Fujii Y; Ishikawa N; Fukuda I; Ishihara S; Kanasaki K
BMC Endocr Disord; 2020 May; 20(1):60. PubMed ID: 32393233
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
[TBL] [Abstract][Full Text] [Related]
13. 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.
Rikhof B; van der Graaf WT; Suurmeijer AJ; van Doorn J; Meersma GJ; Groenen PJ; Schuuring EM; Meijer C; de Jong S
Am J Pathol; 2012 Jul; 181(1):303-12. PubMed ID: 22658485
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the expression and role of IGF pathway biomarkers in human sarcomas.
Lin F; Shen Z; Xu X; Hu BB; Meerani S; Tang LN; Zheng SE; Sun YJ; Min DL; Yao Y
Int J Immunopathol Pharmacol; 2013; 26(1):169-77. PubMed ID: 23527719
[TBL] [Abstract][Full Text] [Related]
15. Investigation of IGF2, Hedgehog and fusion gene expression profiles in pediatric sarcomas.
de Souza RR; Oliveira ID; del Giúdice Paniago M; Yaoita FH; Caran EM; Macedo CR; Petrilli AS; Abib Sde C; de Seixas Alves MT; de Toledo SR
Growth Horm IGF Res; 2014 Aug; 24(4):130-6. PubMed ID: 24846856
[TBL] [Abstract][Full Text] [Related]
16. Utility of characteristic 'Weak to Absent' INI1/SMARCB1/BAF47 expression in diagnosis of synovial sarcomas.
Rekhi B; Vogel U
APMIS; 2015 Jul; 123(7):618-28. PubMed ID: 25912315
[TBL] [Abstract][Full Text] [Related]
17. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
[TBL] [Abstract][Full Text] [Related]
18. Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms.
Hemminger J; Iwenofu OH
Histopathology; 2012 Aug; 61(2):170-7. PubMed ID: 22571292
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
